
## Sarah Calhoun

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5008945/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15. Cancer Biology and Therapy, 2022, 23, 65-75.	3.4	6
2	Prolyl Carboxypeptidase Maintains Receptor Tyrosine Kinase Signaling and Is a Potential Therapeutic Target in Triple Negative Breast Cancer. Cancers, 2022, 14, 739.	3.7	1
3	RBL2/DREAM-mediated repression of the Aurora kinase A/B pathway determines therapy responsiveness and outcome in p53 WT NSCLC. Scientific Reports, 2022, 12, 1049.	3.3	8
4	Acetyl-CoA synthetases ACSS1 and ACSS2 are 4-hydroxytamoxifen responsive factors that promote survival in tamoxifen treated and estrogen deprived cells. Translational Oncology, 2022, 19, 101386.	3.7	11
5	Fatty acid oxidation and autophagy promote endoxifen resistance and counter the effect of AKT inhibition in ER-positive breast cancer cells. Journal of Molecular Cell Biology, 2021, 13, 433-444.	3.3	14
6	Prolyl endopeptidase inhibitor Y-29794 blocks the IRS1-AKT-mTORC1 pathway and inhibits survival and <i>in vivo</i> tumor growth of triple-negative breast cancer. Cancer Biology and Therapy, 2020, 21, 1033-1040.	3.4	5